118 related articles for article (PubMed ID: 14584292)
1. The 2nd conference on Asian trends in prostate cancer hormone therapy.
Akaza H; Chang SJ; Chen KK; Esuvaranathan K; Fujioka T; Hirao Y; Hong SJ; Hinotsu S; Kim WJ; Lau W; Lee SE; Murai M; Naito S; Ogawa O; Rim JS; Soebadi DM; Song JM; Tsukamoto T; Umbas R; Usami M; Yang CR; Yoon JH; Zhou L
Gan To Kagaku Ryoho; 2003 Oct; 30(10):1533-42. PubMed ID: 14584292
[TBL] [Abstract][Full Text] [Related]
2. The 5th Conference on Asian Trends in Prostate Cancer Hormone Therapy.
Akaza H; Moore MA; Chang SJ; Cheng C; Choi HY; Esuvaranathan K; Hinotsu S; Hong SJ; Kim CS; Kim WJ; Murai M; Naito S; Soebadi D; Song JM; Umbas R; Usami M; Xia S; Yang CR
Asian Pac J Cancer Prev; 2007; 8(1):3-12. PubMed ID: 17477764
[TBL] [Abstract][Full Text] [Related]
3. The 3rd Conference on Asian Trends in Prostate Cancer Hormone Therapy.
Akaza H; Naito S; Chang SJ; Chen KK; Cheng C; Choi HY; Fujioka T; Hinotsu S; Hirao Y; Hong SJ; Kim CS; Kim WJ; Lee SE; Murai M; Ogawa O; Rim JS; Soebadi DM; Song JM; Tsukamoto T; Umbas R; Usami M; Xia S; Yang CR; Yoon JH; Zhou L
Gan To Kagaku Ryoho; 2004 Aug; 31(8):1285-95. PubMed ID: 15332559
[TBL] [Abstract][Full Text] [Related]
4. Asian trends in prostate cancer hormone therapy.
Akaza H; Naito S; Cheng C; Kaisary A; Soebadi DM; Umbas R; Esuvaranathan K; Gu FL; Zhou L; Hong SJ; Kim WJ; Lee SE; Rim JS; Song JM; Yoon JH; Chang SJ; Huang CH; Yang CR; Hirao Y; Murai M; Tsukamoto T; Usami M
Gan To Kagaku Ryoho; 2002 Nov; 29(11):1951-61. PubMed ID: 12465395
[TBL] [Abstract][Full Text] [Related]
5. [Surgical and medical treatment for localized prostate cancer].
Kawai K
Gan To Kagaku Ryoho; 2007 Jul; 34(7):1002-5. PubMed ID: 17637535
[TBL] [Abstract][Full Text] [Related]
6. Re: Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level.
Neulander EZ
J Urol; 2004 Feb; 171(2 Pt 1):809; author reply 809-10. PubMed ID: 14713828
[No Abstract] [Full Text] [Related]
7. Management of advanced prostate cancer in Hong Kong: Insights from an APCCC-Derived survey.
Poon DM; Ma WK; Chan TW; Ho FK; Ho LY; Leung AK; Leung SY; Sze HC; Kwong PW; Chan ES
Asia Pac J Clin Oncol; 2019 Oct; 15 Suppl 6():8-13. PubMed ID: 31642191
[TBL] [Abstract][Full Text] [Related]
8. Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease.
Spahn M; Briganti A; Capitanio U; Kneitz B; Gontero P; Karnes JR; Schubert M; Montorsi F; Scholz CJ; Bader P; van Poppel H; Joniau S;
J Urol; 2012 Jul; 188(1):84-90. PubMed ID: 22578727
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant therapy for prostate cancer patients at high risk of recurrence following radical prostatectomy.
Andriole GL
Eur Urol; 1997; 32 Suppl 3():65-9. PubMed ID: 9267788
[TBL] [Abstract][Full Text] [Related]
10. Trends of the primary therapy for patients with prostate cancer in Nara uro-oncological research group (NUORG): a comparison between the CaPSURE data and the NUORG data.
Tanaka N; Fujimoto K; Hirayama A; Yoneda T; Yoshida K; Hirao Y
Jpn J Clin Oncol; 2010 Jun; 40(6):588-92. PubMed ID: 20299498
[TBL] [Abstract][Full Text] [Related]
11. This paper evaluates the natural history of prostate cancer in heterogeneous cohort of men treated with HT.
Yossepowitch O
Eur Urol; 2007 Aug; 52(2):453. PubMed ID: 17674435
[No Abstract] [Full Text] [Related]
12. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer.
Kurek R; Renneberg H; Lübben G; Kienle E; Tunn UW
Eur Urol; 1999; 35 Suppl 1():27-31. PubMed ID: 10081700
[TBL] [Abstract][Full Text] [Related]
13. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
Haines IE; Gabor Miklos GL
J Natl Cancer Inst; 2013 Oct; 105(20):1534-9. PubMed ID: 24092918
[TBL] [Abstract][Full Text] [Related]
15. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
Moul JW; Wu H; Sun L; McLeod DG; Amling C; Donahue T; Kusuda L; Sexton W; O'Reilly K; Hernandez J; Chung A; Soderdahl D
J Urol; 2004 Mar; 171(3):1141-7. PubMed ID: 14767288
[TBL] [Abstract][Full Text] [Related]
16. [Adjuvant hormone therapy in prostatic cancer: after treatment with curative intent. The viewpoint of the urologist].
Martorana G
Recenti Prog Med; 2002 Mar; 93(3):179-82. PubMed ID: 11942170
[No Abstract] [Full Text] [Related]
17. [Endocrine therapy versus observation after R0 resection in node positive prostate cancer].
Kleeberg UR
Strahlenther Onkol; 2000 Jun; 176(6):293-4. PubMed ID: 10897259
[No Abstract] [Full Text] [Related]
18. Patterns of prescription and adherence to European Association of Urology guidelines on androgen deprivation therapy in prostate cancer: an Italian multicentre cross-sectional analysis from the Choosing Treatment for Prostate Cancer (CHOICE) study.
Morgia G; Russo GI; Tubaro A; Bortolus R; Randone D; Gabriele P; Trippa F; Zattoni F; Porena M; Mirone V; Serni S; Del Nero A; Lay G; Ricardi U; Rocco F; Terrone C; Pagliarulo A; Ludovico G; Vespasiani G; Brausi M; Simeone C; Novella G; Carmignani G; Leonardi R; Pinnarò P; De Paula U; Corvò R; Tenaglia R; Siracusano S; Mantini G; Gontero P; Savoca G; Ficarra V;
BJU Int; 2016 Jun; 117(6):867-73. PubMed ID: 26332130
[TBL] [Abstract][Full Text] [Related]
19. Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?
Miyamoto H; Messing EM; Chang C
Nat Clin Pract Oncol; 2005 May; 2(5):236-7. PubMed ID: 16264955
[No Abstract] [Full Text] [Related]
20. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]